![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
666
Mawson Infrastructure
MIGI
Intchains Group
ICG
Bit Origin
BTOG
4
Argo Blockchain
ARBK
5
FRMO CORP
FRMO
US Stock MarketDetailed Quotes
TARA Protara Therapeutics
- 3.545
- -0.775-17.94%
Trading Apr 28 14:58 ET
130.34MMarket Cap-1.63P/E (TTM)
4.090High3.110Low2.32MVolume4.090Open4.320Pre Close8.01MTurnover7.70%Turnover RatioLossP/E (Static)36.77MShares10.48052wk High0.78P/B106.73MFloat Cap1.59552wk Low--Dividend TTM30.11MShs Float800.000Historical High--Div YieldTTM22.69%Amplitude1.040Historical Low3.453Avg Price1Lot Size
Protara Therapeutics Stock Forum
Sign in to post a comment
$Amplify Energy (AMPY.US)$ 18.92%
$Genprex (GNPX.US)$ 30.98%
$Intelligent Group (INTJ.US)$ 17.19%
$Mainz Biomed (MYNZ.US)$ 25.88%
$INVO Fertility (IVF.US)$ (NAYA) 137.07%
$Protara Therapeutics (TARA.US)$ 16.08%
$WW International (WW.US)$ 59.48%
$Genprex (GNPX.US)$ 30.98%
$Intelligent Group (INTJ.US)$ 17.19%
$Mainz Biomed (MYNZ.US)$ 25.88%
$INVO Fertility (IVF.US)$ (NAYA) 137.07%
$Protara Therapeutics (TARA.US)$ 16.08%
$WW International (WW.US)$ 59.48%
5
3
$Protara Therapeutics (TARA.US)$ da phuck is this all about
$Protara Therapeutics (TARA.US)$ going up today???
1
$Protara Therapeutics (TARA.US)$
TARA-002's impressive efficacy in bladder cancer represents significant potential for Protara with durable responses in a difficult-to-treat indication.
These interim Phase 2 results represent a meaningful clinical milestone for Protara Therapeutics. The BCG-Unresponsive NMIBC patient population is particularly important from a regulatory and commercial perspective, as it represents a well-defined group with high unmet medical need. The...
TARA-002's impressive efficacy in bladder cancer represents significant potential for Protara with durable responses in a difficult-to-treat indication.
These interim Phase 2 results represent a meaningful clinical milestone for Protara Therapeutics. The BCG-Unresponsive NMIBC patient population is particularly important from a regulatory and commercial perspective, as it represents a well-defined group with high unmet medical need. The...
3
$Protara Therapeutics (TARA.US)$
TARA-002 shows exceptional 100% initial response and 67% 12-month durability in difficult-to-treat BCG-Unresponsive NMIBC, with excellent safety profile.
The interim results from the Phase 2 ADVANCED-2 trial demonstrate remarkably strong efficacy signals for TARA-002 in both patient populations studied. The 100% complete response rate at any time and 67% 12-month durability in BCG-Unresponsive patients is particularly impressive given the...
TARA-002 shows exceptional 100% initial response and 67% 12-month durability in difficult-to-treat BCG-Unresponsive NMIBC, with excellent safety profile.
The interim results from the Phase 2 ADVANCED-2 trial demonstrate remarkably strong efficacy signals for TARA-002 in both patient populations studied. The 100% complete response rate at any time and 67% 12-month durability in BCG-Unresponsive patients is particularly impressive given the...
1
$Protara Therapeutics (TARA.US)$
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients
1
$Protara Therapeutics (TARA.US)$
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
100% complete response rate at any time...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
100% complete response rate at any time...
2
3
$Protara Therapeutics (TARA.US)$
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Saturday, 26th April at 10:00 am
• TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients
• TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG...
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
Saturday, 26th April at 10:00 am
• TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients
• TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG...
3
2
No comment yet
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Zenyia : may God bless you
Maxxdog : It's great seeing Jag in a stock that I have LOL
Trailside22 Maxxdog : sure reassuring to know Im on the right track when I see the same on his list too.